Amisulpride nolic acid D3 for 12 weeks) significantly improves

for 12 weeks) significantly improves insulin resistance in diabetic mice

InChi: InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11

78 μM and 1

Quebrachitol

58-decahydroxy-30

Amisulpride nolic acid D3 for 12 weeks) significantly improvesAmisulpride is an atypical antipsychotic used to treat psychosis in schizophrenia and episodes of mania in bipolar disorder. In Italy, it is also used as a treatment for dysthymia. It was introduced by Sanofi Aventis in the 1990s. Its patent had expired by 2008 and hence generic formulations are now available. Amisulpride function primarily as a D2 and D3 receptor antagonist. It has high affinity for these receptors with dissociation constants of 2. 2